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Abstract
About 5-10% of breast and ovarian carcinomas are hereditary and most of these result from germline mutations in
the BRCA1 and BRCA2 genes. In women of Ashkenazi Jewish ascendance, up to 30% of breast and ovarian
carcinomas may be attributable to mutations in these genes, where 3 founder mutations, c.68_69del (185delAG)
and c.5266dup (5382insC) in BRCA1 and c.5946del (6174delT) in BRCA2, are commonly encountered. It has been
suggested by some authors that screening for founder mutations should be undertaken in all Brazilian women
with breast cancer. Thus, the goal of this study was to determine the prevalence of three founder mutations,
commonly identified in Ashkenazi individuals in a sample of non-Ashkenazi cancer-affected Brazilian women with
clearly defined risk factors for hereditary breast and ovarian cancer (HBOC) syndrome. Among 137 unrelated
Brazilian women from HBOC families, the BRCA1c.5266dup mutation was identified in seven individuals (5%). This
prevalence is similar to that encountered in non-Ashkenazi HBOC families in other populations. However, among
patients with bilateral breast cancer, the frequency of c.5266dup was significantly higher when compared to
patients with unilateral breast tumors (12.1% vs 1.2%, p = 0.023). The BRCA1 c.68_69del and BRCA2 c.5946del
mutations did not occur in this sample. We conclude that screening non-Ashkenazi breast cancer-affected women
from the ethnically heterogeneous Brazilian populations for the BRCA1 c.68_69del and BRCA2 c.5946del is not
justified, and that screening for BRCA1c.5266dup should be considered in high risk patients, given its prevalence as
a single mutation. In high-risk patients, a negative screening result should always be followed by comprehensive
BRCA gene testing. The finding of a significantly higher frequency of BRCA1 c.5266dup in women with bilateral
breast cancer, as well as existence of other as yet unidentified founder mutations in this population, should be
further assessed in a larger well characterized high-risk cohort.
Keywords: Hereditary breast cancer, Hereditary breast and ovarian cancer Syndrome, Founder mutations, BRCA1
gene, BRCA2 gene
Introduction
Breast cancer is the most common non-cutaneous malig-
nancy in Brazilian women of all ages. In the Southern
and Southeastern States of Brazil, the estimated breast
cancer incidence rates for 2010 reached 64.54 and 64.30
per 100,000 women, the highest in the country [1].
In spite of continuous efforts to improve early detection
and treatment, breast cancer remains the leading cause
of deaths by cancer in Brazilian women. Furthermore,
mortality rates by this type of cancer are still increasing
in the Southern States of the country [2,3].
It is estimated that 5-10% of breast cancers are heredi-
tary, arising from highly penetrant germline mutations in
cancer predisposition genes [4]. A significant proportion
of individuals with hereditary breast cancer have muta-
tions in the tumor suppressor genes BRCA1 (OMIM #
113705) and BRCA2 (OMIM # 600185) [5]. Carriers of
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such mutations are usually predisposed to breast, ovarian,
prostate and other cancers at an early age, a syndrome
known as Hereditary Breast and Ovarian Cancer (HBOC)
[6].
BRCA1 and BRCA2 are similar in their structure and
quite large (100 and 70 kb, respectively). Germline muta-
tions in these genes are usually point mutations, and are
scattered along their entire coding sequences; mutational
hot-spots are uncommon. Deleterious gene rearrange-
ments may also occur in up to 30% of the cases [7].
Therefore, full gene sequencing and rearrangement test-
ing is warranted for accurate diagnosis in most indivi-
duals. In a few populations, however, founder mutations
have been described and are responsible for a significant
proportion of the mutation-positive diagnoses. This is
the case for the c.68_69del and c.5266dup mutations in
BRCA1 and c.5946del mutation in BRCA2 (until recently
referred in the literature as 185delAG, 5382insC and
6174delT, respectively) which are found in 10-12% of
Ashkenazi Jewish women diagnosed with breast cancer
[8,9]. BRCA gene founder mutations have also been
described in other populations, including the Slavic
(BRCA1c.5266dup mutation) [10,11], Finnish and Icelan-
dic (BRCA2999del5 mutation) and German populations
(BRCA1delexon17) [12,13]. In these populations, initial
screening of a clinically suspicious case by testing for
founder mutations is acceptable and allows the diagnosis
of a significant number of carriers using fast and straight-
forward methodologies at a lower cost [14].
In a recent study done in the Brazilian State of Rio de
Janeiro [15], 402 unrelated non-Ashkenazi women affected
with breast cancer were screened for the three Ashkenazi
founder mutations. Of the nine mutation-positive indivi-
duals identified, five (56%) harbored the BRCA1c.5266dup
mutation in exon 20 and the overall prevalence of this par-
ticular mutation in the sample studied was 1.24%. The
women enrolled in the study were not selected for a family
history of the disease, and their ancestry was not
described. A previous study [16] of 47 unrelated breast
cancer-affected women from Rio de Janeiro with a family
history of cancer suggestive of the HBOC syndrome had
already identified the BRCA1c.5266dup mutation in a sig-
nificant proportion of the mutation-positive patients (four
in seven). Interestingly, none of them reported Jewish
ancestry. Finally, Simon et al. [17] reported the occurrence
of the BRCA1c.5266dup mutation in Jewish and non-Jew-
ish HBOC families from the Brazilian State of São Paulo.
Recently, Hamel et al. [18] have studied the c.5266dupC
in 14 different population groups (Russian, Latvian, Ukrai-
nian, Czech, Slovak, Polish, Danish, Dutch, French,
German, Italian, Greek, Brazilian and AJ) and confirmed
that all carriers of this mutation share a common haplo-
type proposing that it arose approximately 1800 years ago
in either Scandinavia or northern Russia and subsequently
spread to the various populations, including the Ashkenazi
Jewish population.
Considering the importance of identifying mutation-
positive HBOC patients for genetic counseling purposes
and the previous reports indicating that founder muta-
tions, in particular BRCA1c.5266dup, may be common in
Brazilian patients diagnosed with breast cancer, we per-
formed this study with the aim of determining the fre-
quency of these mutations in non-Ashkenazi individuals
diagnosed with cancer and whose families fulfilled clini-
cal criteria for the HBOC syndrome.
Patients and Methods
A consecutive sample of 137 unrelated Brazilian patients,
self-referred as non-Ashkenazi and with a significant per-
sonal and/or family history of hereditary breast and ovar-
ian cancer, was evaluated at cancer genetic counseling
services from the two regions with the highest breast
cancer incidence rates in the country in Southern and
Southeastern Brazil: Porto Alegre (from the Cancer
Genetics Clinic of Hospital de Clínicas de Porto Alegre)
and Rio de Janeiro, (from INCA, the Brazilian National
Cancer Institute). All patients confirmed residence in the
States from which they were recruited for at least ten
years, had been diagnosed with cancer or were cancer
unaffected individuals likely to be obligate carriers of
BRCA mutations. A significant family history of HBOC
was defined as presence of either: (a) the American
Society of Clinical Oncology (ASCO) criteria for HBOC
[19] or (b) a prior probability of harboring a BRCA muta-
tion ≥ 30% by pedigree analysis using the Myriad muta-
tion prevalence tables or the Penn II mutation prediction
model [20-22]. Women diagnosed with bilateral breast
cancer under the age of 50 years, regardless of family his-
tory, were also included. All patients relied exclusively on
the public health care system through which BRCA1 and
BRCA2 full gene sequencing is currently not available,
even for patients of very high genetic risk. After signature
of informed consent, genomic DNA was extracted from
peripheral blood by conventional methods [23] and
screening for the founder mutations was performed by
PCR-amplification and DNA sequencing in both direc-
tions using the DYEnamic ET Terminator Cycle Sequen-
cing Kit and the MegabaseorABI automated sequencers.
The amplification and sequencing primer sequences used
were: (a) for BRCA1 exon 2 (c.68_69del mutation): 5’-
GTTCTTTGGTTTGTATTATTCT-3’ and 5’-AGAGGC
AGAGTGGATGGA-3’; (b) for BRCA1 exon 20
(c.5266dup mutation): 5’-ATATGACGTGTCTGCTC-
CAC-3’ and 5’-GGGAATCCAAATTACACAGC-3’. and
(c) for BRCA2exon 11 (c.5946del mutation): 5’-AACGA
AAATTATGGCAGGTTGTTAC-3’ and 5’-GCTTTC
CACTTGCTGTACTAAATCC-3’. All mutation-positive
samples were confirmed in a second independent
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analysis. The amplification and sequencing protocols are
available upon request.
Statistical Analyses
Sample size for this study was estimated using WINPEPI
(PEPI-for-Windows). SPSS version 18.0 was used for data
handling and statistical analyses. For descriptive analysis,
categorical variables were described by their absolute and/
or relative frequencies and quantitative variables were
expressed as mean and standard deviation (SD). The exis-
tence of an association between categorical variables was
examined by chi-square. Association between bilateral
breast cancer and the c.5266dup mutation in a subgroup
analysis of patients with breast cancer were analyzed by
Fishers’ exact test. A significance level of 0.05 was adopted.
Results
Sample characteristics are described in Table 1. The mean
age at cancer diagnosis (all types) was 43.4 years (SD =
10.1; range: 24-73 years). Among the 137 probands
included in the study, 42 (31.0%) were recruited in Porto
Alegre and 95 (69.0%) in Rio de Janeiro.
Most patients (n = 126, 91.9%) had been diagnosed with
breast cancer and of these, 110 (80.3%) were diagnosed
under the age of 50 years. Five patients had been diag-
nosed with tumors other than breast and ovarian cancer
(colorectal cancer, melanoma, gastric cancer, esophageal
cancer, endometrial cancer), but were included because
they had a significant family history of breast and ovarian
cancer in first and second degree relatives. The only can-
cer-unaffected patient in this study was considered an
Table 1 Clinical description of the sample studied (n = 137)
Characteristic N % Mean (SD)
Sex
Female 134 97.8
Male 3 2.2
Age at breast cancer (years)* 42.3 (8.3) range: 24-73
Inclusion criteria
ASCO 113 82.5
Probability of mutation (Myriad) ≥ 30% 62 45.3
Probability of mutation (PENN II model) ≥ 30% 28 20.4
Bilateral breast cancer 34 24.8
Cancer history in the proband (n = 136)**
One primary tumor
Breast cancer 85 62.5
Ovarian cancer 4 2.9
Other# 5 3.7
Multiple primaries:
≥ 2 Breast 31 22.8
≥ 2 ovarian 0 0
1breast and 1 ovarian 2 1.5
≥ 2 Breast and 1 ovarian 3 2.2
At least one breast + other 5 3.7
At least one ovarian + other 1 0.7
Criteria for multiple hereditary cancer syndromes
HBOC + Li-FraumeniLike (Eeles criteria) 23 16.8
HBOC + Li-Fraumeni Like (Birch criteria) 2 1.4
HBOC + Hereditary Breast and Colorectal Cancer 14 10.2
HBOC + Hereditary Non-Polyposis Colorectal Cancer 3 2.2
Cancer family history (1st and 2nd degree relatives)
Number of breast cancer cases 3.3 (1.52)
Number of ovarian cancer cases 1.3 (0.61)
Age at first breast cancer 44.2 (6.8)
*In women with multiple breast cancers, age at the diagnosis of the first primary was considered.
**One patient was cancer unaffected. In the sample of 136 cancer affected probands, there were a total of 184 tumors, including synchronous and metachronous
cases.
#(colorectal, melanoma, gastric, uterine cervix, esophagus, endometrium)
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obligate carrier due to a significant history of breast cancer
in the parental and offspring generations.
Approximately 30.7% of the patients had synchronous or
metachronous multiple primary tumors (n = 42) and the
mean age at first cancer diagnosis in this group was 41.5
years (SD = 6.9; range: 28-61 years). Approximately one-
fourth of the total participants had bilateral breast cancer
(n = 34), and the mean age at the first primary tumor in
this group was 42.2 years (SD = 7.2; range 28-61 years),
similar to the mean age in patients with only one primary
breast cancer (42.3 years; SD = 8.8; range 24-73).
For the entire sample, 45.3% and 20.4% had an estimated
probability of a BRCA gene mutation equal or greater than
30.0% using the Myriad prevalence tables and the Penn II
model, respectively. The mean prior probability of carrying
a BRCA mutation using either method was similar: 24.4%
using the Myriad tables (SD = 3.4, range, 2.8-67.2%) and
22.9% using Penn II (SD = 15.1, range, 7-93%).
Overall, a germline mutation was identified in seven
(5.0%) of the 137 patients studied and in all of them, it
consisted of the c.5266dup mutation in exon 20 of the
BRCA1 gene. A more detailed description of the muta-
tion-positive cases is shown in Table 2. The other foun-
der mutations (c.68_69del in BRCA1 and c.5946del in
BRCA2) were not identified. If only breast or ovarian
cancer-affected probands are considered, the
BRCA1c.5266dup frequency remains similar, 5.3% (7/
131).
Patients diagnosed with bilateral breast cancer were
more likely to carry the BRCA1c.5266dup mutation than
patients with unilateral breast cancer (BRCA1c.5266dup
was present in 4 of 34 patients with bilateral breast can-
cer vs. 1 of 82 unilateral breast cancer patients; p =
0.023). In addition, BRCA1c.5266dup carriers with bilat-
eral breast cancer were younger when first diagnosed
(mean age 38 years; SD = 6; range 33-47) than non-car-
riers (43 years; SD = 7; range 28-61) although this dif-
ference did not reach significance (p = 0.189).
Two of the four metachronous breast cancer mutation
carriers had no family history of breast or ovarian can-
cer and did not fulfill any other inclusion criteria of the
study, apart from the early onset bilateral breast cancer
diagnosis. Both cases, however, had a limited family
structure (fewer than 2 first- or second-degree female
relatives alive and at an age ≥ 45 years in either lineage)
as defined by Weitzel et al. [24].
Families from the Southern region had a significantly
higher number of breast cancer diagnoses in the family
than those from the Southeast (4.0 in versus 3.1, p =
0.004). However, there was no significant difference in the
mean age of breast cancer diagnosis (40.4 and 42.8 years,
respectively, p = 0.206), nor in BRCA1c.5266dup frequency
(3.8% and 4.5%, respectively, p > 0.999) between regions.
Discussion
The identification of individuals at-risk for hereditary
breast cancer is important to ensure that appropriate
risk reducing interventions are offered, to counsel
patients and families regarding recurrence risk and to
guide the decisions about cancer treatment interventions
in affected individuals. The precise identification of
at-risk individuals in a given family depends on the
Table 2 Detailed description of BRCA1c.5266dup-positive probands and their families
Prior Probability of Mutation
in a BRCA gene
Case
#
Cancer
diagnosis
(index-case)
Age at
diagnosis
(ys)
Cancer family history* ASCO
criteria
Limited
Family
Structure
Myriad
Prevalence
Tables (%)
Couch
Prediction
Model (%)
1-RJ Breast 33 MAT Br (F-45) Yes No 16.3 20.0
2-RJ Ovarian 47 PAT Ov (60), Br (F-30), End (64) Yes No 46.8 44.0
3-RS Ovarian 52 MAT Br (F-44), Ov (F-76), Ov (F-66), Ut (F-78), Ut (N/A),
Ga (M-68),
CRC (M-69), HeN (M-N/A), HeN (M-75)
No No 46.8 43.0
PAT Lu (M-N/A), CRC (M-N/A), CRC (F-N/A), Ut (35), Br
(M-62), Ga (M-N/A), Br (F-36), Bilat Br (F-45), Br (F-44), Br
(F-45)
Yes No 40.8 33.0
4-RJ Bilateral Breast 45 and 50 MAT BilatBr (F-45,50), Ov (39) Br (F-49), Bilat Br (F-47,50) Yes No 40.7 31.0
5-RJ Bilateral Breast 46 and 47 PAT Lu (M-N/A), Ga (M-N/A) CRC (M-N/A) No Yes 6.9 9.0
6-RJ Bilateral Breast 33 and 38 - No Yes 6.9 15.0
7-RS Bilateral Breast 35 and 45 MAT Ov (F-58), Ov (F-49), Br (F-90) Br (F-49), Ga (M-70),
Liv (M-70)
Yes No 40.7 47.0
Legend: RJ: family recruited from Rio de Janeiro; RS = family recruited from Porto Alegre;
(*) MAT = cancer history in maternal side of the family, PAT = cancer history in paternal side of the family; other cancer diagnoses in family are indicated by the
abbreviated cancer type (Br = breast, Lu = lung; Ga = gastric Ov = ovarian; Prost = prostate; Esoph = esophageal; Liv = liver; End = endometrial; CRC =
Colorectal; HeN = head and neck cancer; Ut = uterine cancer, not defined whether cervix or endometrium) followed by followed by sex (M = male, F = female)
and age at diagnosis (N/A = not available).
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identification of a deleterious germline mutation in a
cancer predisposition gene. In the case of the HBOC
syndrome, genetic testing is often hampered by the
complexity and cost of testing the BRCA genes, espe-
cially in lower resource countries. In Brazil, such testing
is not yet covered by private insurance nor provided by
the public health care system and its cost in private
laboratories precludes its use for most at-risk families.
The initial screening of founder mutations in BRCA1
and BRCA2 before investigation of their entire coding
regions has been well established in individuals of Ashke-
nazi Jewish ancestry as well as in a few other populations,
and it is considered a cost-effective approach in these
populations [25,26]. In other Latin American commu-
nities, this issue has not been largely explored. An excep-
tion is a large cohort of Latin American HBOC families
studied by Weitzel et al. (2005) [27] in which six recurrent
mutations in BRCA1 accounted for 47% of the deleterious
germline mutations and interestingly, the BRCA1
c.68_69del mutation, one of the Ashkenazi Jewish founder
mutations, occurred in 3.6% of this clinic-based cohort of
predominantly Mexican women. In this study the authors
suggest that an initial diagnostic screen with a panel for
these more commonly observed mutations could be cost-
effective.
Only two reports from Brazilian breast-cancer affected
patients have suggested that a founder BRCA1 mutation,
c.5266dup, may be encountered at a significant prevalence
[16,17]. This mutation is the second most common muta-
tion described in the Breast Cancer Information Core
(BIC) database [28] for HBOC families worldwide. It has
been reported in 14.0%, 10.0%, 6.0% and 4.0% of Ashke-
nazi Jewish, German, Italian and Russian women with
breast cancer [29-32], respectively. It was also described in
a recent study from Portugal, where it appeared in
approximately 1.0% of the series studied [33]. In addition,
in a recent multi-national study, Hamel et al. (2011) [18]
identified this mutation in several European countries. To
our knowledge, it has not been detected in Spain [34,35]
nor in other South American countries, although only a
few comprehensive mutation studies (i.e. including
sequencing of the entire coding region of both genes and
gene rearrangement testing) in HBOC families have been
produced in these regions [34-40]. The penetrance of the
BRCA1c.5266dup mutation has been well defined in Ash-
kenazi women, being associated with a cumulative lifetime
risk of 0.67 for breast cancer and 0.33 for ovarian cancer
[41].
In the present study, we screened 137 unrelated and
self-referred non-Ashkenazi women at high risk for the
HBOC syndrome for the three common founder muta-
tions described in Ashkenazi Jewish cohorts and only
BRCA1c.5266dup was identified, at a frequency of 5.0%.
As expected, this frequency is higher than that described
by the other Brazilian studies, including that of Gomes
et al. [15] and Esteves et al [42], and likely results from
the study design, that defined a significant personal and
familial cancer history as inclusion criterion at
recruitment.
Our results are in agreement with previous prevalence
studies of the c.5266dup mutation in other high-risk non-
Ashkenazi populations, such as the Italian and German
populations [30,31]. The origin of the BRCA1c.5266dup
mutation in Brazilian patients and its relation to the East-
ern-European counterpart remain to be determined. In a
recently published study, da Costa et al. (2008) [43] evalu-
ated the haplotypic profile of seven Brazilian carriers of
c.5266dup and reported that all mutation carriers shared
an identical haplotype, indicating a common origin. Some
authors (i.e. Carvalho Silva et al. [44] and Gomes et al.
[15]) have postulated that the entry of this mutation into
Brazil is related to immigration of European Jews from
Portugal in the sixteenth century. In the report by Weitzel
et al. (2005) [27], that identified the Ashkenazi founder
mutation c.68_69del in Mexican HBOC families, all muta-
tion carriers shared the Ashkenazi Jewish founder haplo-
type. The authors postulate that Mexican carriers of these
mutations are likely descendants of Conversos who immi-
grated to the Americas in the 15th-16th centuries and over
generations assimilated into the larger Hispanic society.
The same reasoning may be applied to the occurrence of
BRCA1c.5266dup in Brazil. However, the absence of this
mutation in studies from Spain or from other South
American countries and the fact that only one case was
reported in Portugal is against this hypothesis. Recent
results from the study of Hamel et al. (2011) [18], show
that the mutation probably originated in Scandinavia or
Northern Russia, was then disseminated in European
populations and thus could have entered Brazil through
one or more of the several large European immigration
waves in the 18th and 19th centuries. A detailed under-
standing of its entrance and distribution in Brazil, remains
to be determined [45,46].
One interesting finding of our study is the high fre-
quency of the c.5266dup mutation in patients with bilat-
eral breast cancer, compared to those with unilateral
breast cancer. It is known that women with bilateral
breast cancer are more likely to carry a BRCA mutation
[47,48]. Gershoni-Baruch et al. (1999) [49], studying
Jewish women with bilateral breast cancer, found a high
prevalence of founder mutations (31.0%), and 3.7% of
the cases carried the c.5266dup mutation. In their
report, bilateral breast cancer per se did not seem to
reflect genetic predisposition unless associated with
early age of onset. In another study that compared
mutation prevalence in women with unilateral, family
history positive and early onset breast cancer and
women with bilateral breast cancer, the distribution of
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BRCA1c.5266dup was not significantly different between
groups [32].
A limitation of our study is that we have not investi-
gated the potential existence of other founder mutations
that could become apparent after gene full gene sequen-
cing; however, there is currently no published evidence
for Brazilian BRCA founder mutations other than
c.5266dup. We did not consider testing for founders
described in Hispanic populations (i.e. Weitzel et al.
(2005) [27]; Rodriguez et al. (2008) [50]) since it is our
understanding that the population from the Brazilian
cities studied here show trihybrid ancestries that are dis-
tinct from the Central American populations as indicated
by studies from Alves-Silva et al. (2000) [51] and Parra
et al. (2003) [52]. Additionally, it has been demonstrated
clearly that even mestizos from different Central and
South American regions have significant intra- and inter-
ethnic variability and admixture profiles [53].
Finally, a debatable point regarding founder mutation
frequency in a given population or high risk group, is
how much is enough to justify screening. Although the
economic analysis of such a question is beyond the scope
of our study, there must be also a concern with the social
and medical consequences of such testing. Given current
knowledge, if a recommendation for screening of founder
BRCA mutations is made for Brazilian HBOC women
without subsequent comprehensive testing, most (likely >
90%) of the mutations carriers would remain unidenti-
fied. Such a recommendation could be erroneously inter-
preted as sufficient, or result in false tranquilization
whenever negative, hampering continuation towards
mutation testing of the entire coding region of both
genes, which could obviously have serious consequences
for these individuals and their families. This concern is
further justified by the inaccessibility to proper cancer
genetic counseling for most high-risk Brazilian women,
and by the lack of coverage through both private and
public health-based insurance of germline mutation test-
ing. Thus, although the frequency of one single mutation,
BRCA1c.5266dup is significant in this subset of Brazilian
women with a personal and familial history of HBOC,
initial screening for one founder mutation in at-risk
patients should be performed in the setting of genetic
counseling and within a cancer risk evaluation program.
In a high-risk patient or family, testing should always
include a comprehensive approach (full gene sequencing
and rearrangement testing for both BRCA genes) when
the initial founder mutation screening is negative.
We conclude that initial screening of the BRCA1
c.5266dup mutation in Brazilian individuals at high risk
for HBOC is justified, but should be considered with
caution. This statement is based on the frequency of the
single founder mutation currently described in this
population, lack of evidence of other founder BRCA
mutants at a significant frequency in Brazil, and poten-
tial consequences of misinterpretation of negative
screening results. These principles may apply to other
highly admixed populations in South America and other
continents.
It is imperative to concentrate efforts in making BRCA
mutation testing and genetic counseling available to all
high-risk patients in Brazil, and in educating health care
professionals in the identification and proper manage-
ment of these individuals. The best strategy for muta-
tion screening and molecular diagnosis of high risk
HBOC families in Brazil will only be fully understood
after a comprehensive knowledge of BRCA mutation
types and frequencies in this population.
Finally, the fact that two of the seven mutation-posi-
tive individuals had a limited family structure reinforce
the importance of recognizing this feature and demon-
strate that criteria for genetic testing must be adapted to
consider this variable. The increased frequency of
BRCA1c.5266dup in women with bilateral breast cancer
should be further assessed in a larger cohort.
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